NCT03875144View on ClinicalTrials.gov

Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2028

Conditions
Peritoneal MesotheliomaPeritoneal Carcinomatosis
Interventions
PROCEDURE

PIPAC

Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks

DRUG

Cisplatin

standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)

DRUG

Pemetrexed

standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)

Trial Locations (1)

34298

Institut réginal du Cancer de Montpellier, Montpellier

All Listed Sponsors
lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER